Search

Displaying results 1851 - 1860 of 8517 in total
  1. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    It has a weak inhibitory effect on GABA receptor binding sites.

  2. Drug

    Dexchlorpheniramine maleate

    go.drugbank.com/drugs/DB09555
    Approved

    Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.

  3. Drug

    Chlorothiazide

    go.drugbank.com/drugs/DB00880
    ApprovedInvestigationalVet approved

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

  4. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine.

  5. Drug

    Agomelatine

    go.drugbank.com/drugs/DB06594
    ApprovedInvestigational

    Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. … The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.

  6. Drug

    Fenoldopam

    go.drugbank.com/drugs/DB00800
    Approved

    A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.

  7. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]

  8. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    [A229083] Available as oral tablets or long-acting intramuscular injections, flupentixol is marketed under brand names such as Depixol and Fluanxol. … [L31808] It has been marketed to manage symptoms of depression in patients who may or may not exhibit signs of anxiety.

  9. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID). … [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action.

  10. Drug

    Conjugated estrogens

    go.drugbank.com/drugs/DB00286
    ApprovedInvestigational

    It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine. … [T484] The currently approved product of conjugated estrogens was developed by Wyeth Ayerst and FDA approved in 2003.[L5608]